Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten - a Single-Center Descriptive Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07168655

Enrollment

163

Registered

2025-09-11

Start date

2023-02-21

Completion date

2025-03-25

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

Obstructive Hypertrophic cardiomyopathy (oHCM)

Brief summary

The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US

Interventions

DRUGMavacamten

According to the product label

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years at index date * Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) * ≥ 4 weeks of follow-up after prescription of mavacamten

Exclusion criteria

* Data collection as part of a clinical trial during the study period * Current participation in a myosin inhibitor clinical trial

Design outcomes

Primary

Measure	Time frame
Participant New York Heart Association (NYHA) functional class	Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Left ventricular outflow tract (LVOT) gradient results at rest, Valsalva and post-exercise (if available)	Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Left ventricular ejection fraction (LVEF) percentage	Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant echocardiogram measurements: Maximum left ventricular wall thickness	Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks
Participant age	Baseline
Participant gender	Baseline
Participant race	Baseline
Participant ethnicity	Baseline
Participant insurance coverage	Baseline
Participant Body Mass Index	Baseline
Participant blood pressure	Baseline
Participant heart rate	Baseline
Participant genotype	Baseline
Participant family history	Baseline
Participant New York Functional Class classification	Baseline
Participant echocardiogram measurements	Baseline
Participant comorbidities	Baseline
Participant hypertrophic cardiomyopathy (HCM) treatment history	Baseline
Mavacamten index dose prescribed	Baseline
Participant obstructive hypertrophic cardiomyopathy (oHCM) symptoms (syncope, shortness of breath, fatigue, exercise intolerance, palpitations)	Baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026